Seres (MCRB) EVP Brady Kelly Receives Shares, Sells 64

What Happened Brady Kelly, EVP and Chief Operating Officer of Seres Therapeutics (MCRB), had restricted stock units convert into 181 shares on Aug 15, 2026. Of those, two zero-dollar dispositions (90 and 91 shares) occurred the same day (representing shares surrendered/withheld in connection with the vesting). Separately, 64 shares were sold in the open market on Aug 17, 2026 at $4.55 per share, generating $291 in proceeds. These actions appear to be routine vesting and tax-related transactions rather than an investment purchase.

Key Details

• Acquisition/Conversion: 181 shares via exercise/conversion of derivative (RSU settlement) on 2026-08-15.
• Withheld/Disposed (no cash): 90 shares and 91 shares on 2026-08-15 at $0.00 (derivative-related dispositions to satisfy tax obligations).
• Open-market sale: 64 shares sold on 2026-08-17 at $4.55 per share, proceeds $291; sale effected under a Rule 10b5-1 plan adopted Nov 26, 2025 (per footnote).
• Shares owned after the transactions: Not specified in the provided filing excerpt.
• Filing date: Form 4 filed 2026-08-18 (within the standard two-business-day window).
• Relevant footnotes: F1 clarifies each RSU = right to one share; F2 confirms the sale was pursuant to a 10b5-1 plan to cover taxes; F3/F4 describe the RSU vesting schedule and that RSUs have no expiration.

Context The filing reflects RSU vesting/settlement and routine tax-related actions. The zero-dollar disposals indicate shares were surrendered or withheld to meet tax withholding obligations when RSUs settled; the small open-market sale was executed under a pre-existing 10b5-1 plan to cover taxes. These transactions are administrative/tax-driven and not the same signal as an outright discretionary purchase or large sale intended as a market bet.